Document Type
Article Presentation
Original Publication Date
2024
Date of Submission
April 2025
Abstract
This paper explores the potential of stem cell transplantation as a treatment for neurodegenerative diseases, specifically Alzheimer’s. While previous clinical trials, including those for amyotrophic lateral sclerosis, have demonstrated the safety of cellular therapies, identifying effective stem cell lines is crucial for advancing similar trials in Alzheimer’s. Using the APP/PS1 mouse model the study presents a pre-clinical proof-of-concept where human neural stem cells were transplanted into the fimbria fornix. Results showed significant cognitive improvements in hippocampal-dependent memory tasks at both 4 & 6 weeks post-transplantation. Interestingly, while the levels of synapse-associated proteins and cholinergic neurons remained unchanged, there was a marked reduction in amyloid plaque accumulation in treated mice, which correlated with increased activation of microglia. Further in vitro experiments revealed that these stem cells could stimulate microglial activity and promote amyloid phagocytosis, suggesting an immunomodulatory function. Notably, by the end of the study, stem cells were no longer detectable via IHC or PCR, raising the possibility that either integration into native tissue occurred or that temporary engraftment was insufficient for therapeutic effects, potentially reducing the need for ongoing immunosuppression. Overall, the study supports further preclinical investigation into human neural stem cells as a promising and safe therapeutic approach for Alzheimer’s disease.
Rights
© The Author(s)
Description
https://www.nature.com/articles/s41598-018-33017-6